Article
Hematology
M. Gerde, E. Ibarra, R. Mac Kenzie, C. Fernandez Suarez, C. Heer, R. Alvarez, M. Iglesias, J. Balparda, E. Beruti, F. Rubinstein
Summary: Adding hydroxychloroquine to classical treatments in patients with refractory primary obstetric APS can increase the rate of live births and reduce the prevalence of pregnancy complications.
THROMBOSIS RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Stanley Niznik, Micha J. Rapoport, Orly Avnery, Aharon Lubetsky, Ronen Shavit, Martin H. Ellis, Nancy Agmon-Levin
Summary: Thrombotic events following diagnosis are common among female patients with primary antiphospholipid syndrome regardless of disease presentation. Heart valve disease and ANA positivity may be risk factors for thrombosis during follow-up of patients presenting with pure obstetric antiphospholipid syndrome.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cell Biology
Jing Liu, Liting Zhang, Yijia Tian, Shuting Wan, Min Hu, Shasha Song, Meihua Zhang, Qian Zhou, Yu Xia, Xietong Wang
Summary: Obstetric antiphospholipid syndrome (OAPS) is a serious disease that threatens the health of pregnant women. Hydroxychloroquine (HCQ) has shown potential benefits in refractory OAPS, and its therapeutic mechanism involves reversing the effects of antiphospholipid antibodies on trophoblast cells, improving pregnancy outcomes, and reducing the incidence of pathological pregnancy.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Article
Obstetrics & Gynecology
Marta Tonello, Antonia Calligaro, Maria Favaro, Teresa Del Ross, Paola Veronese, Elisa Salvan, Maria Teresa Gervasi, Amelia Ruffatti
Summary: The study aimed to evaluate the long-term risk of thrombosis after pregnancy in women with purely obstetric antiphospholipid syndrome (OAPS) and identify the risk factors for thrombosis in OAPS patients. The incidence of thrombotic events was not significantly different between OAPS patients and aPL carriers, with arterial thrombosis and cerebrovascular events being the most frequent types of vascular involvement. The presence of lupus anticoagulant was a significant risk factor for thrombosis in both OAPS patients and aPL carriers who developed thrombosis.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2021)
Article
Surgery
Grace F. F. Chao, Jie Yang, Alex Peahl, Jyothi R. Thumma, Justin B. Dimick, David E. Arterburn, Dana A. Telem
Summary: This study used data from the IBM MarketScan database to examine the incidence and outcomes of bariatric surgery patients who gave birth. The study found that giving birth was common within the first 2 years after surgery and was not associated with an increased risk of reinterventions. This suggests that clinicians should focus on shared decision-making and maternal safety when discussing pregnancy after bariatric surgery.
Review
Immunology
Xue Peng, Xi Tan, Aiyun Xing
Summary: Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized by recurrent thrombosis and pregnancy complications. Obstetrical APS (OAPS) specifically refers to APS in pregnant women. The classification criteria for OAPS have generated discussion due to the possibility of excluding certain patients. This article presents two cases of non-criteria OAPS with severe complications and discusses the diagnosis, treatment, and prognosis of this unusual antenatal event. It also provides an overview of the pathogenetic mechanisms and clinical features of OAPS.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Chieko Mineo, Philip W. Shaul, Bonnie L. Bermas
Summary: Antiphospholipid syndrome is an autoimmune disease characterized by the presence of antibodies against phospholipids, which leads to thrombosis and pregnancy-related complications. Recent research has focused on discovering novel mechanisms underlying obstetric APS.
CLINICAL IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Kenji Tanimura, Shigeru Saito, Sayaka Tsuda, Yosuke Ono, Hajime Ota, Shinichiro Wada, Masashi Deguchi, Mikiya Nakatsuka, Takeshi Nagamatsu, Tomoyuki Fujii, Gen Kobashi, Hisashi Arase, Hideto Yamada
Summary: The anti-beta 2-glycoprotein I/HLA-DR antibody is associated with antiphospholipid syndrome and recurrent pregnancy loss. This study demonstrates that the antibody is significantly associated with adverse obstetric outcomes and recurrent pregnancy loss.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Yongjing Luo, Jiayang Jin, Yani Yan, Mengyao Zhang, Lei Hou, Yuke Hou, Qiuyan Pei, Chun Li
Summary: This study aims to assess the risk factors and possible associations between bleeding complications and adverse pregnancy outcomes (APOs) in patients with antiphospholipid syndrome (APS). The results show that mucocutaneous hemorrhage may be an indication of the occurrence of APOs in obstetric patients with APS.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Victor M. Martinez-Taboada, Pedro Blanco-Olavarri, Sara Del Barrio-Longarela, Leyre Riancho-Zarrabeitia, Ana Merino, Alejandra Comins-Boo, Marcos Lopez-Hoyos, Jose L. Hernandez
Summary: This study compares the characteristics, features, serology, and outcomes of women with obstetric antiphospholipid syndrome (APS) to those with non-criteria (NC)-APS and seronegative (SN)-APS. The study found that the cardiovascular risk burden was higher in the APS group and patients with APS criteria received more intensive treatment. However, with the addition of standard of care (SoC) treatment, fetal-maternal outcomes were similar among all groups, with significant improvement in live births and a decrease in adverse pregnancy outcomes (APO).
Article
Medicine, Research & Experimental
Ying Xing, Lina Wen, Jia Zhang, Haiyan Li, Jing Ma
Summary: Adverse pregnancy outcomes are a devastating reality in clinics, with factors such as lupus anticoagulant positivity and angiogenic markers being correlated with poor pregnancy outcomes and neonatal health.
CLINICAL AND EXPERIMENTAL MEDICINE
(2022)
Review
Endocrinology & Metabolism
Shenghan Xu, Miao Liu, Jiamu Xu, Bangwei Che, Wenjun Zhang, Wei Li, Tao Huang, Ying Yu, Cheng Zha, Zheng Peng, Kunyuan Huang, Kaifa Tang
Summary: This case report shares the management experience of a patient with pregnancy combined with adrenal adenoma causing ACTH-independent Cushing's syndrome (CS), accompanied by obstetric antiphospholipid syndrome (OAPS) and severe pre-eclampsia. The patient underwent laparoscopic adrenal tumor resection under general anesthesia at 23 weeks of gestation and cesarean section at 39 weeks to give birth to a healthy baby girl with an Apgar score of 10. Pregnancy complicated by CS is rare and difficult to diagnose, but diagnostic methods such as 24-hour urinary free cortisol, cortisol circadian rhythm, ultrasound, and MRI can be helpful. Furthermore, this case highlights the importance of recognizing and treating OAPS in patients with CS during pregnancy.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Immunology
Arsenio Spinillo, Camilla Bellingeri, Irene De Maggio, Greta Riceputi, Maria Paola Pandolfi, Carolina Spada, Claudia Alpini, Carlomaurizio Montecucco, Fausta Beneventi
Summary: The study found that patients with APS are more likely to have a high-risk aPL profile and a higher rate of adverse pregnancy outcomes, while CTDs are associated with an increased risk of adverse obstetric outcomes. Low-risk antibody carriers are more likely to contribute to adverse obstetric events compared to high-risk patients, and single positivity is associated with a higher burden of obstetric complications compared to double/triple positivity.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY
(2021)
Article
Developmental Biology
Enrique Esteve-Valverde, Jaume Alijotas-Reig, Cristina Belizna, Joana Marques-Soares, Ariadna Anunciacion-Llunell, Carlos Feijoo-Masso, Luis Saez-Comet, Arsene Mekinian, Raquel Ferrer-Oliveras, Elmina Lefkou, Stephanie Morales-Perez, Ariel Hoxha, Angela Tincani, Cecilia Nalli, Josep Pardos-Gea, Luca Marozio, Aldo Maina, Gerard Espinosa, Ricard Cervera, Sara De Carolis, Omar Latino, Sebastian Udry, Elisa Llurba, Carmen Garrido-Gimenez, Laura Trespidi, Maria Gerosa, Cecilia B. Chighizola, Patrizia Rovere-Querini, Valentina Canti, Karoline Mayer-Pickel, Sara Tabacco, Anna Arnau, Francesc Miro-Mur
Summary: This study analyzed a cohort of 1048 women with OAPS and found that 21.3% of women had low complement levels during pregnancy. Compared to women with normal complement levels, those with low complement levels had shorter pregnancy length, lower neonatal survival rate, higher fetal loss rate, and some placental vasculopathies. Therefore, proper treatment can improve adverse pregnancy outcomes related to low complement levels.
Article
Rheumatology
Jui-Hung Kao, Ting-Yuan Lan, Cheng-Hsun Lu, Chiao-Feng Cheng, Yi-Min Huang, Chieh-Yu Shen, Song-Chou Hsieh
Summary: This study investigated the neonatal and maternal outcomes of patients treated with belimumab during pregnancy. A total of 13 pregnancies were included in the study, and it was found that there was no increased risk of fetal anomalies or severe infection in patients exposed to belimumab during pregnancy.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2021)
Article
Obstetrics & Gynecology
A. D. Makatsariya, E. Slukhanchuk, V. O. Bitsadze, J. K. H. Khizroeva, M. Tretyakova, V. Tsibizova, I Elalamy, J-C Gris, E. Grandone, N. A. Makatsariya, T. Mashkova
Summary: The severe complications of COVID-19 infection involve various conditions, including thrombotic microangiopathy (TMA). This article summarizes the main types, pathogenesis, and treatment principles of TMA, and discusses the possible pathological models in patients with COVID-19.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
(2022)
Article
Hematology
Jean-Christophe Gris, Eva Cochery-Nouvellon, Chloe Bourguignon, Eric Mercier, Sylvie Bouvier, Isabelle Quere, Antonia Perez-Martin, Nicolas Molinari, Eric Matzner-Lober
Summary: This study retrospectively analyzed consecutive prescriptions for thrombophilia screening in a French university hospital from 2010 to 2019. The results provide reference values for several coagulation parameters and examine the associations between these parameters and thrombophilic outcomes. These findings are important for validating laboratory results and assessing their originality.
THROMBOSIS RESEARCH
(2022)
Article
Hematology
Jean-Christophe Gris, Chloe Bourguignon, Sylvie Bouvier, Eva Nouvellon, Jeremy Laurent, Antonia Perez-Martin, Eve Mousty, Mariya Nikolaeva, Jamilya Khizroeva, Victoria Bitsadze, Alexander Makatsariya
Summary: This study retrospectively examined thrombotic outcomes during pregnancy following an initial combined oral contraceptive (COC)-associated venous thromboembolic (VTE) event and analyzed factors associated with recurrence. The results showed a significant rate of VTE recurrence during pregnancy and puerperium, despite thromboprophylaxis treatment with low-molecular-weight heparin.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Cardiac & Cardiovascular Systems
Jean-Christophe Gris, Florence Guillotin, Mathias Chea, Chloe Bourguignon, Sylvie Bouvier
Summary: Pregnancy and puerperium increase the relative risk of venous thromboembolism, with a low absolute risk. Risk factors have a greater impact after childbirth. Methods for VTE risk assessment are emerging and should be used systematically for thromboprophylaxis.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Hematology
Jean-Christophe Gris, Florence Guillotin, Mathias Chea, Chloe Bourguignon, Eva Nouvellon, Sylvie Bouvier
Summary: Antiphospholipid antibodies are associated with pregnancy complications and require early prognosis and customized treatment. Women with aPL antibodies are at risk of thrombosis and psychiatric disorders even after pregnancy. Furthermore, aPL antibodies may have systemic impact, requiring further research and prevention.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2023)
Article
Hematology
Jean-Christophe Gris, Chloe Bourguignon, Sylvie Bouvier, Eva Nouvellon, Jeremy Laurent, Antonia Perez-Martin, Eve Mousty, Mariya Gennadevna Nikolaeva, Jamilya Khizroeva, Victoria Bitsadze, Alexander Makatsariya
Summary: This study retrospectively analyzed data of patients who experienced thrombotic events after taking combined oral contraceptives, and found a low risk of recurrence, which was influenced by classical risk factors. These observational data may provide clues for future research.
THROMBOSIS RESEARCH
(2022)
Letter
Hematology
Florence Guillotin, Mathieu Fortier, Marie Portes, Christophe Demattei, Lea Cultrera, Maxime Loyens, Eve Mousty, Eva Nouvellon, Eric Mercier, Chloe Bourguignon, Mathias Chea, Vincent Letouzey, Jean-Christophe Gris, Sylvie Bouvier
THROMBOSIS RESEARCH
(2023)
Article
Hematology
Jean-Christophe Gris, Florence Guillotin, Taissa Pereira dos Santos, Mathias Chea, Paul Loubet, Didier Laureillard, Albert Sotto, Laurent Muller, Saber Davide Barbar, Claire Roger, Jean-Yves Lefrant, Boris Jung, Kada Klouche, Thibault Mura, Isabelle Quere, Antonia Perez-Martin
Summary: In this study, thrombin generation assays were performed on severe COVID-19 patients, and it was found that these assays could not predict the early or late survival rates of the patients, nor were they associated with thrombotic events. However, by detecting the changes in endogenous thrombin potential (ETP), it was possible to predict whether patients would need to be transferred to an intensive care unit in the future.
THROMBOSIS RESEARCH
(2023)
Article
Medicine, General & Internal
Mathieu Fortier, Mathias Chea, Charlene Ain, Maxime Loyens, Thierry Boudemaghe, Jean-Christophe Gris, Sylvie Bouvier
Summary: The study evaluates the association between NEU-SFL measured after admission of COVID-19 patients and in-hospital survival or death. The results indicate that patients with higher NEU-SFL values are more likely to die, and the changes in NEU-SFL values can reflect the recovery status of the patients.
FRONTIERS IN MEDICINE
(2022)
Review
Hematology
Benjamin Brenner, Emmanouil Papadakis, Ian A. Greer, Jean-Christophe Gris
Summary: The management of pregnant women with thrombophilia and gestational vascular complications is still a matter of debate, as current treatment is often based on clinical outcome rather than disease mechanism. Guidelines for venous thromboembolism prophylaxis in pregnancy are inconsistent due to limited evidence. This review critically discusses risk assessment models and management strategies for high-risk pregnant women, emphasizing the importance of an individualized precision medicine approach based on disease mechanism.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Nilufar R. Gashimova, Liudmila L. Pankratyeva, Victoria O. Bitsadze, Jamilya Kh. Khizroeva, Maria V. Tretyakova, Kristina N. Grigoreva, Valentina I. Tsibizova, Jean-Christophe Gris, Natalia D. Degtyareva, Fidan E. Yakubova, Alexander D. Makatsariya
Summary: This study assessed the inflammatory response of the fetus due to the effects of COVID-19 on the mother during pregnancy. The results showed that COVID-19 infection in pregnant women can lead to fetal inflammatory response syndrome, which has adverse consequences for the newborn's life and health.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Hematology
Jean-Christophe Gris, Mariya Gennadevna Nikolaeva, Jamilya Khizroeva, Victoria Bitsadze, Alexander Makatsariya, Sylvie Ripart, Antonia Perez-Martin
Summary: This article reports 20 cases of first venous thromboembolism (VTE) events in women of childbearing age after evidence of intimate partner violence. Most patients did not report the violence at their first consultation and doctors did not suspect it. This situation may be underdiagnosed and calls for systematic evaluation. Screening for intimate partner abuse could have significant consequences regarding the protection of affected women and the assessment of bleeding risk with anticoagulant treatment.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)